Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, ...
New Delhi: With India recording a sharp rise in early-onset obesity, insulin resistance and fatty liver disease, Metropolis Healthcare has rolled out three scientifically curated metabolic health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback